News items New method to prevent ovarian cancer increases quality of life
8 June 2021

Researchers at the Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after a fallopian tube removal with delayed ovarian removal to prevent ovarian cancer. Because women with this mutation have an increased risk of ovarian cancer in addition to breast cancer, it is recommended that the fallopian tubes and ovaries be removed simultaneously around the age of forty, resulting in an early menopause. With treatment where only the fallopian tubes are removed first and the ovaries at a later date, women do not enter menopause early, which improves quality of life.

Women with a BRCA1 or BRCA2 mutation have an increased risk of developing ovarian cancer, which is 44% with BRCA1 and 17% with BRCA2. This is significantly higher than the risk for the average Dutch woman (1.3%). Moreover, ovarian cancer in an early stage gives few symptoms, it is not easy to diagnose early and the prognosis is often unfavorable. Women with a BRCA mutation are now advised to remove their fallopian tubes and ovaries around the age of 40 to reduce the risk of ovarian cancer. This is a very effective treatment, but can lead to many adverse effects. In fact, by removing the fallopian tubes and ovaries, women enter an early menopause, with various consequences both in the short term (hot flashes, night sweats, sexual problems) and in the long term (cardiovascular disease, osteoporosis and cognitive problems). These symptoms can result in a reduced quality of life and can only be partially resolved with hormones.

Large national study

In order to limit the early menopause and the reduced quality of life of this group of patients after such a preventive operation, the Radboudumc, with the support of KWF cancer control, launched a national study in 2015 on an alternative: removing the fallopian tubes, but leaving the ovaries in place for the time being. The 577 patients who participated in this study came from different UMCs and regional hospitals in the Netherlands. "In fact, there are very strong indications that ovarian cancer often develops not in the ovaries but in the fallopian tubes. By removing the fallopian tubes first and leaving the ovaries in place until the women are at most 45 years old (BRCA1) or 50 years old (BRCA2), we can delay menopause and thus improve quality of life," says Miranda Steenbeek, first author of the article now published in JAMA Oncology

Quality of life

The study found that women who opted for fallopian tube removal had a better menopause-related quality of life than women who had both the fallopian tubes and ovaries removed with the currently common treatment. Fallopian tube removal was also found to show an improvement over the group of women who used hormone therapy after standard treatment. Not only did the quality of life turn out better, but the sexual functioning of the women who were operated on according to the new method was also better. A very promising result. Within this study, quality of life was the main focus, but not yet whether it works to prevent ovarian cancer and what the impact is on the long-term effects of early ovarian removal, such as a higher risk of cardiovascular disease. So far, none of the patients have developed ovarian cancer after a fallopian tube removal, but the women have not been followed long enough to draw any conclusions from this. Because of the extensive safety regulations, this fallopian tube removal with delayed ovarian removal is only offered in a study setting. In order to determine the safety and influence on the prevention of ovarian cancer, a large international follow-up study has been started from the Radboudumc. The results of this study are expected in ten to fifteen years.

This study was conducted under the direction of Joanne de Hullu, Rosella Hermens and Nicoline Hoogerbrugge.

About the publication in JAMA Oncology
Salpingectomy with delayed oophorectomy instead of salpingo-oophorectomy to improve quality of life in BRCA1/2 carriers (TUBA study): a multicenter preference trial -  Miranda P. Steenbeek, Marline G. Harmsen, Nicoline Hoogerbrugge, Marieke Arts-de Jong, Angela H.E.M. Maas, Judith B. Prins, Johan Bulten, Steven Teerenstra, Majke H.D. van Bommel, Helena C. van Doorn, Marian J.E. Mourits , Marc van Beurden, Ronald P. Zweemer, Katja N. Gaarenstroom,  Brigitte F.M. Slangen, Monique M.A. Brood-van Zanten, M. Caroline Vos, Jurgen M.J. Piek, Luc R.C.W. van Lonkhuijzen, Mirjam J.A. Apperloo, Sjors F.P.J. Coppus, Leon F.A.G. Massuger, Joanna IntHout, Rosella P.M.G. Hermens, Joanne A. de Hullu.

More information


Pauline Dekhuijzen

wetenschaps- en persvoorlichter

neem contact op

Related news items


Biomarkers for pyridoxine-dependent epilepsy identified by untargeted metabolomics and infrared ion spectroscopy

24 June 2021

Karlien Coene, theme Metabolic Diseases, and colleagues published in the Journal of Clinical Investigation that untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy.

read more

Two science talents to foreign top institutes with Rubicon

21 June 2021

Rubicons for Michelle Brouwer and Guido van Mierlo

read more

Radboud university medical center and Astherna join forces for new therapy for Stargardt disease

17 June 2021

RNA therapy for patients with a severe inherited retinal disease

read more

The international dataset for colorectal local excisions is published

16 June 2021

Iris Nagtegaal and colleagues presented their first paper on the colorectal cancer dataset and published this in the journal Gastroenterology.

read more